Transforming the lives of patients with life-limiting diseases of the nervous system.
Acquiring, developing and commercializing transformative medicines.
We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. Our dedicated team is restless about ensuring our therapies ultimately reach patients with life-limiting diseases.
Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).
At Engrail, we apply a ‘science-first’ approach.
With our team’s thorough biological understanding of disease, we use rational therapeutic targeting to identify compounds with the greatest promise. We maximize our success by prioritizing acquisition of validated, clinical-stage compounds.
Our unique, flexible transaction model enables us to embrace a broad, open-minded way of thinking. By deploying thoughtful and creative development strategies, we can rapidly progress our therapies through development to commercialization.
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced two key executive appointments.
Engrail is built on the foundation of a tight-knit group of entrepreneurs that embrace the right risks to achieve results. We foster integrity, diversity, transparency and clear communication. We are resilient and hold ourselves and each other accountable.
Are you interested in joining our ambitious and energetic team?